Sex Transm Dis by Singh, Vidisha et al.
Transgender Women Have Higher Human Papillomavirus 
Prevalence Than Men Who Have Sex With Men—Two U.S. Cities, 
2012–2014
Vidisha Singh, MSPH*, Beau Gratzer, MPP†, Pamina M. Gorbach, MHS, DrPH‡, Richard A. 
Crosby, PhD§, Gitika Panicker, PhD¶, Martin Steinau, PhD¶, Raiza Amiling, MPH*, Elizabeth 
R. Unger, PhD, MD¶, Lauri E. Markowitz, MD*, Elissa Meites, MD, MPH*
*Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers 
for Disease Control and Prevention, Atlanta, GA
†Howard Brown Health, Chicago, IL
‡Department of Epidemiology, Fielding School of Public Health, University of California at Los 
Angeles, Los Angeles, CA
§College of Public Health, University of Kentucky at Lexington, Lexington, KY
¶Division of High-Consequence Pathogens and Pathology, National Center for Emerging and 
Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA
Abstract
Background: Human papillomavirus (HPV) prevalence is high among men who have sex with 
men (MSM), yet little is known about HPV among transgender women (TGW). We assessed HPV 
prevalence and knowledge among TGW compared with MSM.
Methods: We enrolled TGW and MSM aged 18 to 26 years from clinics in Chicago and Los 
Angeles during 2012 to 2014. Participants self-reported gender identity, HIV status, HPV 
knowledge, and vaccination status. Self-collected anal and oral specimens were tested for HPV 
DNA (37 types); serum was tested for HPV antibodies (4 vaccine types). Prevalence among 
unvaccinated TGW and MSM was compared using prevalence ratios (PRs) and 95% confidence 
intervals (CIs). Participants without DNA or serologic evidence of HPV were considered naïve.
Results: Among 1033 participants, 49 were TGW. Among 44 TGW and 855 MSM who were 
unvaccinated, any HPV DNA was detected in anal specimens from 39 (88.6%) TGW and 606 
(70.9%) MSM (PR, 1.3; 95% CI, 1.1–1.4), and oral specimens from 4 (9.1%) TGW and 81 (9.5%) 
MSM (PR, 1.0; 95% CI, 0.4–2.5). Antibodies were detected among 37 (84.1%) TGW and 467 
(54.6%) MSM (PR, 1.5; 95% CI, 1.3–1.8). Most participants were naïve to 1 or more HPV vaccine 
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type/s, including 29 (65.9%) TGW and 775 (90.6%) MSM (PR, 0.7; 95% CI, 0.6–0.9). Most TGW 
(55.1%) had never heard of HPV vaccine.
Conclusions: Among TGW, HPV prevalence was high and knowledge was low. Most were still 
naïve to 1 or more HPV vaccine type. Although vaccination ideally occurs prior to exposure, 
findings support existing national recommendations to vaccinate TGW and MSM, and suggest 
additional outreach might increase vaccination.
Human papillomavirus (HPV) is the most common sexually transmitted infection. Among 
sexually experienced 14- to 59-year-olds in the United States, prevalence of any genital HPV 
was 45.8% among men and 40.1% among women during 2013 to 2014.1 A recent meta-
analysis found prevalence of any HPV is 2 to 5 times higher among men who have sex with 
men (MSM), compared with men who have sex exclusively with women (MSW); any anal 
HPV prevalence was highest among HIV-positive MSM (81%) and lowest among HIV-
negative MSW (12%).2 However, little is known about HPV prevalence among transgender 
women (TGW).
Vaccines against HPV were first introduced in 2006; all protect against HPV types 16 and 
18, which cause the majority of HPV-related cancers. Quadrivalent and 9-valent HPV 
vaccines (Gardasil and Gardasil 9; Merck & Co., Inc., Kenilworth, NJ) protect against low-
risk HPV types that cause anogenital warts and also high-risk HPV types that can cause 
anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancers.3 The 9-valent HPV 
vaccine was first licensed in 2015 and has been the only vaccine distributed in the United 
States since late 2016.
The Advisory Committee on Immunization Practices has recommended U.S. HPV 
vaccination for females since 2006 and males since 2010 and has explicitly included 
transgender people since 2016.3,4 Vaccination is routinely recommended for all U.S. 
adolescents at age 11 or 12 years (can start at age 9 years), and catch-up vaccination is 
recommended through age 26 years. Vaccination is recommended for special populations 
including MSM and transgender persons.3,4
Transgender people face a unique set of health challenges, including barriers and lack of 
access to health care.5 In a 30-year population-based study in Sweden, overall mortality was 
significantly higher among sex-reassigned persons than controls of the same sex at birth 
(adjusted hazard ratio, 2.8; 95% CI, 1.8—4.3).6 Transgender women also face extremely 
high rates of other sexually transmitted infections, including HIV. A study at 26 U.S. clinics 
providing STD services reported that among 506 TGW, 13.1% tested positive for chlamydia 
and 12.6% tested positive for gonorrhea at 1 or more anatomic sites.7 In contrast, estimated 
national prevalence is 1.7% for chlamydia and 0.32% for gonorrhea among cisgender men 
aged 15 to 24 years in the United States,8 and among MSM tested at STD clinics, 11.1% 
were positive for urogenital gonorrhea, 10.2% for rectal gonorrhea, 7.9% for pharyngeal 
gonorrhea, 8.4% for urogenital chlamydia, 14.1% for rectal chlamydia, and 2.9% for 
pharyngeal chlamydia.9 A systematic review suggested HIV prevalence is 28% among all 
TGW and 56% among black TGW in the United States.10 HIV infection is of particular 
importance to HPV epidemiology; a 2018 meta-analysis found that with HIV coinfection, 
Singh et al. Page 2
Sex Transm Dis. Author manuscript; available in PMC 2020 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
risk of HPV acquisition is approximately doubled and the rate of HPV clearance is 
approximately halved.11
Because TGW are not often specifically included in epidemiological studies, data are 
lacking on prevalence and risk factors for many health conditions in this population, 
potentially hampering the application of effective interventions.12 To address the lack of 
information about HPV epidemiology among TGW, we assessed HPV prevalence and 
vaccine knowledge among TGW compared with cisgender MSM.
METHODS
Between July 2012 and August 2014, the Young Men’s HPV (YMHPV) cross-sectional 
study enrolled 1033 participants, including TGW and gay, bisexual, and other MSM, from 2 
community health clinics serving lesbian, gay, transgender, and bisexual (LGBT) 
populations in Los Angeles, CA and Chicago, IL. Detailed methods for the YMHPV study 
have been described previously.13,14 The study protocol was reviewed and approved by 
institutional review boards at the participating institutions.
Eligible participants met the following criteria at enrollment: (1) aged 18 to 26 years; (2) 
assigned male sex at birth, regardless of current gender identity or expression; and (3) ever 
had a male sex partner and/or identified as gay/homosexual or bisexual. Most participants 
were enrolled and completed all study components during their usual clinic visit; HPV 
vaccine was not provided as part of the study.
A computer-assisted self-interview collected data on demographic characteristics including 
gender identity (cisgender male, TGW, or other), sexual behavior, and other risk factors for 
persistent HPV infection including self-reported HIV status and smoking, vaccinations, and 
knowledge and attitudes regarding HPV and HPV vaccine. Survey data were collected using 
Qualtrics (Qualtrics, Provo, UT). Each participant was assigned a unique study ID code, and 
no personally identifying information was collected.
Each participant submitted 3 biological specimens, including a self-collected oral rinse, self-
collected anal swab, and blood drawn by clinician or phlebotomist. After handwashing, anal 
specimens were self-collected by inserting a sterile swab 1 inch into the anus and rotating it 
360 degrees at least twice. Oral specimens were self-collected by swishing and gargling 10 
mL of sterile saline for 30 seconds. Illustrated schematics were provided to aid specimen 
self-collection.13 Specimens were shipped to the HPV laboratory at CDC for processing. 
Testing for HPV DNA was conducted on the oral and anal specimens by Linear Array 
Genotyping Assay (Roche Diagnostics, Indianapolis, IN) for detection of 37 HPV types (6, 
11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 
68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, and IS39). Serum specimens were tested for 
presence of antibodies to quadrivalent HPV types (6, 11, 16, and 18) using multiplex direct 
virus-like particle ELISA on a Meso Scale Discovery electrochemiluminescent platform.15 
A participant was considered to have current infection if HPV DNA was detected from the 
oral or anal specimen, and past exposure if HPV antibody was detected from the serum 
specimen.
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Among all participants who completed the study, we analyzed data from those who 
identified as transgender, compiling descriptive statistics regarding demographics, health 
care use, sexual behavior, and HPV knowledge. For study participants who were considered 
unvaccinated (ie, did not report receipt of any HPV vaccine), we assessed characteristics and 
then compared HPV prevalence and seroprevalence among TGW compared with cisgender 
MSM, by calculating prevalence ratios (PR) and 95% confidence intervals (CI) using 2-
tailed Fisher exact test and log binomial regression, with SAS 9.4 (SAS Institute Inc., Cary, 
NC). A P value less than 0.05 was considered significant. The HPV prevalence and 
seroprevalence outcomes were stratified by HIV status, but multivariate analysis was not 
conducted given the lack of variability in HPV exposure to support modeling parameters. 
For this analysis, “any HPV” refers to any of the 37 types detected by Linear Array, and 
“vaccine type HPV refers to any of the 4 HPV types protected against by quadrivalent HPV 
vaccine. Participants with no DNA or serologic evidence of HPV were considered naïve to 
that HPV type.
RESULTS
Of 1033 participants, a total of 49 identified as TGW. Most TGW were aged 22 to 26 years 
(63.3%), non-Hispanic black (61.2%), from the Chicago site (89.8%), and had completed 
high school (63.3%) (Table 1). Many identified as gay/homosexual or bisexual (67.4%). 
Most reported having ever had sex (89.8%), with a median age at first sex of 15 years, and 
median number of 6 (interquartile range [IQR], 2–12) lifetime sex partners. Over a quarter 
(26.5%) reported being HIV-positive. Less than half of participants had health insurance 
(44.9%), but the majority had visited a health care provider in the past 12 months (81.6%). 
Most had discussed their sexual orientation or sexual behavior with their usual health care 
provider (67.4%), and an even greater proportion felt that they could disclose such 
information if important to their health (79.6%). Five (10.2%) reported receiving any HPV 
vaccination; 3 reported being vaccinated as a young adult in the 22- to 26-year-old age 
range, and the other 2 were vaccinated at a younger age.
Among 899 unvaccinated participants, 44 were TGW and 855 were cisgender MSM. 
Compared with unvaccinated MSM, unvaccinated TGW were significantly more likely to be 
non-Hispanic black race/ethnicity, less educated, enrolled from the Chicago site rather than 
the Los Angeles site, and to report being HIV-positive (Table 2). Compared with 
unvaccinated MSM, unvaccinated TGW were significantly less likely to have ever had sex, 
and they had significantly fewer lifetime sex partners; they were also significantly less likely 
to identify as gay/homosexual or to have smoked 12 or more cigarettes in the past year. No 
significant difference was found in age group, age at first sex, health insurance status, health 
care provider visits, or disclosure.
Among unvaccinated participants, HPV prevalence was high. In total, 43 (97.7%) of 44 
unvaccinated TGW had evidence of current infection with or past exposure to any HPV type, 
significantly higher than the 80.8% prevalence of any HPV among MSM (PR, 1.2; 95% CI, 
1.1–1.3); any vaccine type was detected in 90.9% of TGW and 64.0% of MSM (PR, 1.4; 
95% CI, 1.3–1.6) (Table 3). In anal specimens, HPV prevalence was significantly higher in 
TGW versus MSM, with any HPV detected in 88.6% versus 70.9% (PR, 1.3; 95% CI, 1.1–
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1.4), and any vaccine type detected in 50.0% versus 36.4% (PR, 1.4; 95% CI, 1.0–1.9), 
respectively. In oral specimens, HPV prevalence was lower overall, and there was no 
significant difference between TGW and MSM, with any HPV detected in 9.1% versus 9.5% 
(PR, 1.0; 95% CI, 0.4–2.5), and any vaccine type detected in 2.3% versus 3.0% (PR, 0.7; 
95% CI, 0.1–5.4), respectively. Serum antibody to any HPV vaccine type was detected in 
84.1% of TGW compared with 54.6% of MSM (PR, 1.5; 95% CI, 1.3–1.8). Although most 
participants were naïve to at least 1 HPV vaccine type, including 29 (65.9%) TGW and 775 
(90.6%) MSM, TGW were significantly less likely than MSM to be naïve to an HPV 
vaccine type (PR, 0.7; 95% CI, 0.6–0.9). Transgender women were also significantly less 
likely than MSM to be naïve to HPV type 16 (36.4% vs. 67.8%; PR, 0.5; 95% CI, 0.4–0.8). 
Significant differences in anal HPV and seropositivity were maintained after stratification by 
HIV status.
Human papillomavirus knowledge was low among TGW. Less than half were aware that 
multiple sex partners can increase the risk of acquiring HPV, that HPV can be transmitted 
during oral, anal, or vaginal sex, that HPV can cause oropharyngeal cancer, or that HPV can 
cause anal cancer. More than half (55.1%) reported that before participating in the study, 
they had never heard of HPV vaccine. Some (38.8%) indicated an intent to get HPV vaccine 
in the future. Many were not at all sure (40.8%) that they would be able to get an HPV 
vaccine if they wanted (Table 4).
DISCUSSION
In this study conducted at LGBT clinics in 2 cities in the United States, prevalence of HPV 
infection was even higher among TGW than among MSM, a group with known high 
prevalence of HPV and HPV-related diseases. This can be partly but not fully explained by 
the significantly higher HIV prevalence among TGW, even though TGW had significantly 
fewer lifetime sex partners than MSM in this study. Human immunodeficiency virus 
prevalence is known to be high among TGW worldwide, with a pooled HIV prevalence of 
21.7% (95% CI, 18.4–25.1) reported in 1 meta-analysis,16 in line with the HIV prevalence 
self-reported by TGW participating in this study. However, studies have noted discrepancies 
between self-reported HIV prevalence and laboratory-confirmed HIV prevalence, suggesting 
that some TGW may be unaware of their HIV status.17 Undiagnosed HIV among TGW 
might help explain the higher HPV prevalence that we observed among TGW compared 
with MSM. Additionally, the high HPV prevalence among young TGW might be further 
explained by factors not assessed in this study, such as sexual networks or sexual assault, 
reported by 47% of transgender people in a U.S. national survey.18
HPV vaccination is most effective when administered prior to exposure to HPV vaccine 
types. In our study, most TGW had evidence of current infection with or past exposure to 
HPV. Many participants had been previously infected with HPV type 16, as only 36.4% of 
TGW and 67.8% of MSM were naïve to this HPV type. Evidence of so many current and 
past HPV infections in the 18- to 26-year age group highlights the importance of vaccination 
at younger ages. Nevertheless, the majority of TGW were still naïve to at least 1 of the 4 
quadrivalent HPV vaccine types.
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Low uptake of HPV vaccine was found in both TGW and MSM and may reflect the fact that 
the study was conducted within a few years of the change in vaccine recommendations to 
include men as well as women.14 However, this study sheds light on the very low knowledge 
base among TGW regarding HPV and HPV vaccine. Transgender people through age 26 are 
explicitly included among the groups for whom HPV vaccine is routinely recommended.4 
Additional outreach and education for this population might increase awareness and uptake 
of public health interventions, such as HPV vaccination, HIV screening, and other 
recommended health care.
Only a few other studies of HPV prevalence among TGW have been conducted, all outside 
the United States: 3 studies assessed anal HPV and 1 study assessed neovaginal HPV. 
Prevalence varied by anatomical site examined and HIV prevalence among participants. In a 
study of sex workers in Argentina, among 273 TGW with a median age of 29 years, 97.4% 
tested positive for any anal HPV.19 In Peru, a study of 68 TGW aged 18 to 40 years found 
anogenital prevalence was 95.6% for any HPV and 35.3% for quadrivalent vaccine types.20 
In Indonesia, Thailand, and Malaysia, any anal HPV was detected in 80.6% of participants 
in a cohort including 344 MSM and 48 TGW aged 18 years and older; data were not 
reported separately for TGW and MSM.21 In the Netherlands, 1 study of neovaginal HPV 
among 54 TGW aged 19 to 60 years reported a prevalence of high-risk HPV types of 20% 
after a median postoperative time of 2.4 years.22 The prevalence of 88.6% for any HPV in 
anal specimens among TGW in the YMHPV study is in line with these studies, and, as 
expected, slightly lower than the prevalence reported in studies that did include TGW older 
than 26 years.
This analysis is subject to several limitations. First, participants probably are not 
representative of all TGW in the United States, particularly those in rural areas or who do 
not attend LGBT health clinics. Because having a male sex partner was an inclusion 
criterion for the study, our study participants might have been more likely to have male sex 
partners relative to TGW in general. We did not assess gender confirmation surgery. Second, 
self-reported data may be affected by social desirability bias, especially for stigmatized 
information, such as HIV status or sexual behavior, although this type of bias should be 
minimized by computer-assisted self-interview. Third, self-collected specimens can be 
challenging, but our results support the feasibility of self-collected anal swabs among 
transgender people.23 Also, we did not assess HPV sero-prevalence for the nine 9-valent 
HPV vaccine types; presumably an even greater proportion of TGW and MSM are naïve to 
at least 1 of the 9-valent vaccine types than were found to be naïve to the quadrivalent 
vaccine types assessed in this study. Genital HPV prevalence was not assessed in this study. 
Finally, due to small sample size, we were unable to identify factors to fully explain the high 
HPV prevalence observed among TGW in this sample.
Our study identified high rates of HPV infection among both TGW and MSM, reinforcing 
the importance of routine vaccination before onset of sexual activity. Although vaccination 
ideally occurs prior to HPV exposure, most TGW were still naïve to at least 1 HPV vaccine 
type; these results support national recommendations to vaccinate TGW and MSM who are 
within the recommended target age range for vaccination, even if they are already sexually 
active. Gender-neutral routine and catch-up vaccination policies may be helpful to increase 
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HPV vaccination uptake among TGW. In addition, TGW may benefit from reducing 
structural barriers to health care and gender-affirming approaches.5,18 Further evidence is 
needed to develop recommendations regarding appropriate screening and treatment for HPV-
related diseases among TGW.
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TABLE 1.
Characteristics of Participating Transgender Women
n %
Total 49 100.0
Age, y
 18–21 18 36.7
 22–26 31 63.3
Race/ethnicity
 Non-Hispanic white 0 0.0
 Non-Hispanic black 30 61.2
 Non-Hispanic Asian/Pacific Islander 1 2.0
 Hispanic /Latino (any race) 8 16.3
 Other/unknown 10 20.4
Education
 Less than high school 3 6.1
 High school diploma or equivalent 31 63.3
 Some college/2-year or technical degree 7 14.3
 4-year degree or equivalent/higher 4 8.2
 Other/unknown 4 8.2
City, state
 Chicago, IL 44 89.8
 Los Angeles, CA 5 10.2
Sexual orientation
 Gay/homosexual 19 38.8
 Bisexual 14 28.6
 Heterosexual/straight 8 16.3
 Other/unknown 8 16.3
Ever had sex
 Yes 44 89.8
 No/unknown 5 10.2
Lifetime sex partners
 Median (interquartile range) 6 2–12
Lifetime sex partners
 0 4 8.2
 1–5 14 28.6
 6–10 8 16.3
 >10 11 22.5
 Other/unknown 12 24.5
Age at first sex 15 12–18
 Median (interquartile range)
HIV status, self-reported
 HIV-positive 13 26.5
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n %
 HIV-negative 24 49.0
 Other/unknown 12 24.5
Smoking
 Never 15 30.6
 Smoked ≥12 cigarettes in past year 3 6.1
 Smoked <12 cigarettes in past year 27 55.1
 Other/unknown 4 8.2
Health insurance
 Any 22 44.9
 None or unknown 27 55.1
Visited health care provider in past 12 mo
 Yes 39 79.6
 No or unknown 10 20.4
Discussed sexual orientation/behavior with usual health care provider
 Yes 33 67.4
 No or unknown 16 32.7
Ever received any HPV vaccination
 Yes 5 10.2
 No or unknown 44 89.8
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TABLE 3.
HPV Prevalence Among All Unvaccinated Participants (N = 899), by Body Site and Gender Identity
TGW MSM
n % n % PR (95% CI)
Any site
 Any HPV* 43 97.7 691 80.8 1.2 (1.1–1.3)
 Vaccine type/s† 40 90.9 547 64.0 1.4 (1.3–1.6)
Anal
 Any HPV* 39 88.6 606 70.9 1.3 (1.1–1.4)
 Vaccine type/s†‡ 22 50.0 311 36.4 1.4 (1.0–1.9)
Oral
 Any HPV*   4   9.1 81   9.5 1.0 (0.4–2.5)
 Vaccine type/s†   1   2.3 26   3.0 0.7 (0.1–5.4)
Serum
 Vaccine type/s† 37 84.1 467 54.6 1.5 (1.3–1.8)
Naïve‡
 Naïve to ≥1 vaccine type†‡ 29 65.9 775 90.6 0.7 (0.6–0.9)
 Naïve to HPV type 16‡ 16 36.4 580 67.8 0.5 (0.4–0.8)
*Any of 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 
83, 84, 89, IS39).
†At least 1 quadrivalent vaccine type (HPV 6, 11, 16, 18).
‡
Participants were considered naïve if they had no anal, oral, or serologic evidence of infection with that HPV type.
Bold indicates significance.
TGW indicates transgender women; MSM, men who have sex with men.
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